(American Journal of Pathology. 2001;158:367-372.)
© 2001 American Society for Investigative Pathology
Suprabasal Overexpression of the hsRPB7 Gene in Psoriatic Epidermis as Identified by a Reverse Transcriptase-Polymerase Chain Reaction Differential Display Model Comparing Psoriasis Plaque Tissue with Peritonsillar Mucosa
Raik Böckelmann*,
Peter Neugebauer
,
Nuschin Djahan Paseban*,
Martin Hüttemann*,
Harald Gollnick* and
Bernd Bonnekoh*
From the Department of Dermatology and Venereology,*
Otto-von-Guericke-University, Magdeburg, Germany; and the Department of
Otorhinolaryngology,
University of Cologne,
Köln, Germany
 |
Abstract
|
|---|
In psoriasis an etiopathogenetic vicious circle is nowadays
hypothesized that the disease is triggered by skin-specific autoantigen
structures, the expression and accessibility of which are
positively correlated with the intensity of the hyperproliferation and
inflammation in the epidermopapillary compartment driven by
autoreactive T cells. Despite the close microanatomical relation
between skin and mucosa, clinicians have always been intrigued
by the observation that psoriatic affection of the mucosa, if
at all existing, is only seen as very rare events in the lips
and tongue sparing buccopharyngeal sites. This prompted us to establish
an experimental model system comparing psoriatic-involved skin and
peritonsillar mucosa from tonsillectomies by a reverse
transcriptase-polymerase chain reaction/differential display strategy.
Among more than 60 cDNA species to be displayed in psoriasis,
but missing in peritonsillar mucosa, one species was identified
as coding for the RNA polymerase IIA seventh subunit (hsRPB7 gene) as a
most critical factor for DNA to RNA transcription. Immunohistochemistry
showed a hitherto unknown, distinctive pattern of hsRPB7
expression that was 1) tissue type-dependent with a surplus in skin
keratinocytes and a near absence in peritonsillar mucosa, 2)
tightly regulated by the keratinocyte differentiation process with a
sharp suprabasal up-regulation in contrast to a basal
down-regulation, and 3) substantially augmented in
psoriatic-involved skin as compared to normal and psoriatic uninvolved
skin. Keratinocytes of actinic keratoses also showed a strong hsRPB7
expression that however did not strictly spare the basal cell layer
presumably reflecting the disturbed intraepidermal stratification
because of the premalignant status of these precancerous
lesions.
 |
Introduction
|
|---|
The etiology of psoriasis is still
unknown.1-7
But there is a lot of at least indirect
clinical and experimental evidence that speaks in favor of a
predominantly immunological quality of its pathogenesis. Nowadays,
autoantigen-directed mechanisms intermingled with microbial
(super)-antigen-driven immune-activations are hypothesized to play
major roles in psoriasis, with the primary relevance of T-cell actions
prevailing over antibody-mediated processes.4-11
In this
pathogenetic concept it is a matter of current controversial debates if
such putatively expressed HLA-restricted autoantigens are recognized by
CD4+ or CD8+
lymphocytes.2,3,12,13
Nevertheless, an alternate
etiological concept of psoriasis as a disease with an
antigen-independent pathogenesis has still to be taken into careful
consideration. Only very recently, the possible crucial involvement of
components of the innate immune systems including natural killer
characteristics of T cells has been brought to the awareness of the
scientific community.4,5,14
Moreover, the obvious clinical
diversity of psoriasis and its variants lends support to the notion
that heterogeneic pathomechanism may co-exist, as well as combinations
thereof.
Whether the oral mucosa can be specifically affected by psoriasis is an
open question.15-18
This is partly because of the general
observation, that signs of a possible psoriatic involvement of the oral
mucosa are only seen in rare cases, mostly in conjunction with pustular
skin manifestations of psoriasis.19-22
In such cases, the
lips may show an exfoliative psoriatic cheilitis, and usually the
tongue presents with an exfoliatio areata linguae (ie, a so-called
geographical tongue or benign migratory glossitis). The latter
manifestation is histologically characterized by intraepithelial
microabscesses of neutrophilic leukocytes also known as a quite
pathognomonic feature of psoriatic skin affection.19,20,23
Attempts have been made to explain the rarity of thus still
questionable psoriatic involvement of oral mucosa by pointing to the
fact that in this tissue compartment the epithelial proliferation rate
reaches under physiological conditions already such a high level that
hypothetically may not be further increased in a psoriasis-typical
manner.21
But this explanation seems to be insufficient to
a certain extent, as it relates only to epithelial hyperproliferation
without addressing the phenomenon that an inflammatory infiltrate as
another histological hallmark of psoriatic skin manifestation is
usually missing in the oral mucosa of psoriasis patients. Therefore an
alternate hypothesis might be raised postulating: 1) the missing
expression or accessibility of putative psoriasis-relevant autoantigens
or 2) the lack of psoriasis-determining antigen-independent alterations
of gene expression, respectively, in oral mucosa as possible decisive
reasons for its common noninvolvement in the psoriatic disease process.
Most interestingly, the manifestation of psoriasis in a split-skin
graft transplanted into the oral cavity has recently been reported
emphasizing the crucial pathogenetic role of the epidermodermal
compartment in psoriasis.24
Given these considerations, we have established an experimental model
comparing directly the gene expression between psoriatic plaque tissue
and oral peritonsillar mucosa by a differential display/reverse
transcriptase polymerase chain reaction (DD/RT-PCR) approach. As
reported herein, this strategy led to the identification of more than
60, until now unknown, cDNA species up-regulated in the psoriatic
plaque as compared to the mucosa background. Additionally, this
comparison showed an overexpression of the transcription-related hsRPB7
gene in psoriasis, which was analyzed by immunohistochemistry in
detail.
 |
Materials and Methods
|
|---|
Nonradioactive Differential Display RT/PCR
Our recent nonradioactive modification25
of the
original DD/RT-PCR protocol26
was used as a technique for
an optimized visualization and PCR reamplification of differentially
displayed cDNA bands detected by silver staining. In brief, tissue
specimens from skin lesions of plaque psoriasis, normal skin, and
tonsillectomy-derived peritonsillar mucosa27
were frozen
in liquid nitrogen and then homogenized on ice (Polytron PT3000,
Kinematica AG). Total RNA was isolated by the standard
guanidinium isothiocyanate method (RNAzol B), and mRNA was purified by
a single run through an oligo(dT)-cellulose spun column (Pharmacia).
The cDNA resulting from reverse transcription with anchored primers
T12AN was used as a template in a 20-µl PCR
reaction containing 1 µmol/L of the T12AN
primer and an arbitrary 10-mer primer28
each, 2.5 U
AmpliTaq DNA polymerase (Perkin Elmer), 200 µmol/L dNTP, and 2 mmol/L
MgCl2. Kinetics of the PCR reactions were set to
10 minutes at 94°C, 41 cycles of 30 seconds at 94°C, 30 seconds at
42°C, and 60 seconds at 72°C with a 10 minutes termination step at
72°C. The PCR-amplified cDNA species were separated
electrophoretically on polyester film-backed 10% polyacrylamide gels
(CleanGel, ETC) under nondenaturing flatbed conditions at 15°C.
The cDNA bands were detected by an optimized silver staining as
described in detail earlier.25
From the differential display gels those cDNA bands were cut out that
were identified for psoriatic tissue but found to be missing for normal
oral mucosa when comparing corresponding lanes running side-by-side.
The cDNA polyacrylamide material was intensely chopped by scalpel
cuttings and squashed by a micropestle. The extraction was performed in
a 0.5 mol/L ammonium acetate/1 mmol/L ethylenediaminetetraacetic acid
solution (pH 8.0) at 37°C overnight under vigorous shaking. After
centrifugation, the supernatant was glass microfiber-filtered (2-µm
pore size, Whatman) to remove polyacrylamide remnants. The cDNA was
ethanol-precipitated, redissolved, ethanol-reprecipitated, and washed,
as well as vacuum-dried for the subsequent PCR reamplification under
the conditions given above.25
The PCR reamplification
product was run in a 0.8% low-melting agarose gel, subcloned
(pCR2.1-TOPO; Invitrogen) and submitted to a nonradioactive
cycle-sequencing reaction (Thermo Sequenase, Amersham). Sequencing was
performed by using UV-polymerized gels (Repro Gel Long Read) in
conjunction with an automated sequencer (ALFexpress, Pharmacia).
Immunohistology
For this purpose, biopsies of psoriatic plaques, peritonsillar
mucosa, uninvolved psoriatic, and normal skin as well as seborrheic and
actinic keratoses (n = 3 to 6 donors each) were
placed in frozen specimen-embedding medium (catalog no. 6769006;
Shandon, Pittsburgh, PA), quickly frozen on a freezing block at -55 to
-60°C, cut into 5-µm slices using a microtome, and fixed with
acetone (4°C, 10 minutes). The slides were incubated with a murine
monoclonal anti-RPB7-antibody (dilution 1:500; BAb Co., Richmond,
CA)29,30
with a subsequent detection by an alkaline
phosphatase Vectastain ABC kit (catalog no. AK-5002; Vector
Laboratories Inc., Burlingame, CA) in conjunction with a Vector red
substrate kit (catalog no. SK-5100, Vector Laboratories, Inc.).
Endogenous alkaline phosphatase activity was blocked by adding its
inhibitor levamisole to the substrate solution. Nuclei were
counterstained with Mayers hemalaun solution (catalog no.
1.09249.0500; Merck, Darmstadt, Germany). Mounting of the slides was
performed by the use of Kaisers glycerin gelatin (catalog no.
1.09242.0100, Merck). Technical negative controls were performed by
omitting the first antibody.
 |
Results
|
|---|
The study identified more than 60 cDNA species that were expressed
in the psoriatic plaque but not in the normal buccopharyngeal mucosa.
When analyzing these cDNA data by comparison with GenBank data from the
National Center for Biotechnology Information using the BLAST 2.0
search routine (www.ncbi.nlm.nih.hov/cgi-bin/BLAST), the main body of
the cDNA species was found to contain until now unknown sequence
information. The novel data were registered at GenBank receiving
appropriate accession numbers and are communicated in Table 1
.
View this table:
[in this window]
[in a new window]
|
Table 1. Panel of 65 Novel cDNA Species Found to Be Up-Regulated in
Psoriatic-Involved Skin as Compared to Normal Peritonsillar Mucosa when
Performing a Differential Display/RT-PCR Analysis
|
|
A certain cDNA species with a 338-bp length, which appeared to be
overexpressed in the psoriatic plaque as compared to oral mucosa as
well as normal skin (Figure 1)
, was found
to be identical with the hsRPB7 gene (GenBank identification
U52427; corresponding positions 5553 to 5890) as a human homologue of
yeast RPB7 coding the seventh subunit of RNA polymerase
II.31-33
Because of the until now unknown expression
pattern of the hsRPB7 protein in psoriasis, we undertook a thorough
immunohistological analysis giving the following results.

View larger version (87K):
[in this window]
[in a new window]
|
Figure 1. A: Differential display gel demonstrating the
psoriasis-related overexpression of a 338-bp cDNA species
(arrow) that
was eventually identified as representing the hsRPB7 gene coding a
protein critically involved in DNA to mRNA transcription. S,
bp-standard; M, peritonsillar mucosa; N, normal skin; P,
psoriatic-involved skin. B: Sequence of the cDNA species
containing part of exon 7, all of intron 7, and part of exon 8 from the
hsRPB7 gene overexpressed in psoriasis plaque tissue as compared to
peritonsillar oral mucosa.
|
|
In peritonsillar mucosa there was no substantial expression of hsRPB7
detectable (Figure 2E)
. For psoriatic
plaques we found a strong hsRPB7 expression mostly in the cytoplasm of
the keratinocytes in the upper two thirds of the subcorneal epidermis,
ie, in the stratum spinosum, whereas the basal and, in some instances,
also the first suprabasal cell layers were spared (Figure 2, AC)
.
Normal epidermis and uninvolved psoriatic skin showed only a weak to
moderate expression of hsRPB7 also restricted to the suprabasal layers
(Figure 2D)
. Overall, we did not observe any substantial hsRPB7
expression in the capillaries, inflammatory cells, or fibrocytic
elements of the subepidermal or subepithelial compartments of involved
and uninvolved psoriatic as well as normal skin nor peritonsillar
mucosa, respectively.

View larger version (153K):
[in this window]
[in a new window]
|
Figure 2. Immunohistochemical detection of hsRPB7 protein expression as a red
reaction product confined mostly to the cytoplasm of epidermal
keratinocytes with blue counterstaining of the nuclei. In the psoriatic
plaque the hsRPB7 protein was expressed strongly in the suprabasal and
subcorneal epidermis with a sparing of the basal and, partly, the first
suprabasal epidermal cell layers. Original magnifications: x125
(A), x250
(B), and x500
(C). In normal
skin there was only a weak to moderate hsRPB7 expression [original
magnification, x500
(D)], but
again restricted to the suprabasal epidermal compartment without
involvement of the basal epidermis. Notably, the peritonsillar mucosa
showed only a faint hsRPB7 protein expression [original magnification,
x500 (E)],
confirming the RT/PCR differential display data. The cell
differentiation-related tight down- and up-regulation of hsRPB7 as a
critical transcription factor in the basal and suprabasal compartment,
respectively, was proven as an obviously general phenomenon in normal
(D) as well as
psoriatic epidermis
(C).
|
|
To investigate the specificity of these findings for the psoriatic
disease process, the immunohistological study was extended to some
other forms of hyperkeratotic diseases. The hsRPB7 expression proved to
be weak to moderate in seborrheic keratoses (n =
3) as well as in one case of ichthyosis vulgaris
(n = 1), but to be very strong in actinic
keratoses (n = 3) representing precancerous
lesions. Notably, in actinic keratoses the basal cell layers were not
so strictly spared from the hsRPB7 expression.
Overall, a distinct pattern of RPB7 expression was observed, nearly
completely missing in the peritonsillar mucosa epithelium, and being
restricted to the suprabasal epidermis under nonpremalignant conditions
with a much higher intensity in involved psoriatic skin as compared to
normal and uninvolved psoriatic skin.
 |
Discussion
|
|---|
With regard to the contribution to the further elucidation of the
etiopathogenesis of psoriasis, DD-RT/PCR techniques have already been
used to compare involved and uninvolved psoriatic skin.34
We now propose an alternate model comparing psoriatic plaque tissue and
peritonsillar mucosa based on the clinical notion that despite the
close microanatomical relation between both tissues, the latter is
never involved by the psoriatic disease process. The DD/RT-PCR
comparison of psoriatic-involved skin with normal peritonsillar mucosa
is an attractive research objective aiming at the identification of
gene products that might be critically involved in the etiopathogenesis
of psoriasis with regard to 1) the epidermal hyperproliferation, 2) the
vascular inflammatory compartment, as well as 3) putatively involved
autoantigens. The project led to the discovery of so far unknown DNA
sequence information that has to be further characterized and
identified at the nucleotide and protein level.
The main outcome of our study is the hitherto unknown differential
expression of the hsRPB7 gene in psoriatic and normal skin as well as
peritonsillar mucosa. The corresponding product, which we picked up by
DD-RT/PCR and identified by sequencing, contains part of exon 7, all of
intron 7, and part of exon 8 from the hsRPB7 gene. Therefore this cDNA
species may represent a pre-mRNA as well as an alternatively spliced
form of hsRPB7 mRNA, in which intron 7 is not spliced out, leading to a
modification in the C-terminus of the protein.
As a pivotal part of the DNA transcription machinery the hsRPB7 protein
was found to be nearly absent in the peritonsillar mucosa epithelium
and to be expressed suprabasally in the epidermis with a much higher
abundance in involved psoriatic skin as compared to uninvolved
psoriatic and normal skin. Overexpression of hsRPB7 did not seem to be
strictly psoriasis-specific because we could observe this phenomenon
also in actinic keratoses. However, there was a difference in the
pattern of hsRPB7 expression between psoriatic plaques and actinic
keratoses. Most interestingly, the latter expressed hsRPB7 also in
major parts of the basal cell layer as a presumptive special feature of
the disturbances related to the premalignant transformation occurring
in these precancerous lesions.
Originally the RPB7 gene product has been characterized as a 19-kd
subunit of the RNA polymerase II oligopolypeptide complex in the yeast
Saccharomyces cerevisae functioning as an essential factor
for cell growth and viability.35
Surface plasmon resonance
studies demonstrated that the yeast RPB7 protein together with RPB4
stabilizes a pre-initiation complex consisting of promoter DNA, TATA
box-binding protein, transcription factor TFIIB, as well as the RNA
polymerase II being responsible for mRNA generation as a prerequisite
for protein translation.36
Only recently the existence of an evolutionarily conserved human
homologue to RPB7 was shown, ie, hsRPB7.31-33
Until now
the knowledge about the regulation of mRNA and protein expression of
hsRPB7 in the skin under physiological and pathophysiological
conditions is rather limited. Our data point to an up-regulation of
hsRPB7 protein expression and thus DNA-mRNA transcription during the
psoriasis dependently disturbed keratinocyte differentiation process in
the upper epidermis. This finding seems to be another, novel facet
reflecting the disturbed intraepidermal cell differentiation process in
psoriasis. A very striking feature under psoriatic and normal tissue
conditions was the spared hsRPB7 expression in the basal epidermal
cells, an obvious cell differentiation-related phenomenon getting lost
under premalignant conditions that awaits further characterization.
 |
Acknowledgements
|
|---|
We thank Mrs. J. Leipold for excellent technical assistance.
 |
Footnotes
|
|---|
Address reprint requests to Prof. Dr. Med. B. Bonnekoh, Universitätsklinik für Dermatologie und Venerologie, Otto-von-Guericke-Universität, Leipziger Strasse 44, D-39120 Magdeburg, Germany. E-mail: bernd.bonnekoh{at}medizin.uni-magdeburg.de
Supported by grant FKZ 2587A/0027H from the "Kultusministerium des Landes Sachsen-Anhalt" (to B.B.) and the Jean-Uhrmacher Foundation, Cologne (to P.N.).
Accepted for publication October 13, 2000.
 |
References
|
|---|
-
Griffiths CEM: Immunological pathways in psoriasis. ed 3 Roenigk HH, Jr Maibach HI eds. Psoriasis, 1998, :pp 341-348 Dekker New York
-
Austin LM, Coven TR, Bhardwaj N, Steinmann R, Krueger JG: Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 1998, 25:79-88[Medline]
-
Jenisch S, Henseler T, Nair RP, Guo SW, Westphal E, Stuart P, Kronke M, Voorhees JJ, Christophers E, Elder JT: Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet 1998, 63:191-199[Medline]
-
Nickoloff BJ: Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999, 104:1161-1164[Medline]
-
Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135:1104-1110[Free Full Text]
-
Karasek MA: Progress in our understanding of the biology of psoriasis. Cutis 1999, 64:319-322[Medline]
-
Nickoloff BJ: The search for pathogenic T cells and the genetic basis of psoriasis using a severe combined immunodeficient mouse model. Cutis 2000, 65:110-114[Medline]
-
Christophers E: The immunopathology of psoriasis. Int Arch Allergy Immunol 1996, 110:199-206[Medline]
-
Dudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I: Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999, 117:580-586[Medline]
-
Bonnekoh B, Huerkamp C, Wevers A, Geisel J, Sebök B, Bange F-C, Greenhalgh DA, Böttger EC, Krieg T, Mahrle G: Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-
. J Invest Dermatol 1995, 104:58-61[Medline]
-
Nickoloff BJ, Wrone-Smith T: Superantigens, autoantigens, and pathogenic T cells in psoriasis. J Invest Dermatol 1998, 110:459-460[Medline]
-
Behrendt C, Gollnick H, Bonnekoh B: Up-regulated perforin expression of CD8+ blood lymphocytes in generalized non-anaphylactic drug eruptions and exacerbated psoriasis. Eur J Dermatol 2000, 10:1-5
-
Nickoloff BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999, 155:145-158[Abstract/Free Full Text]
-
Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA: Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999, 135:546-552[Abstract/Free Full Text]
-
Morris LF, Phillips CM, Binnie WH, Sander HM, Silverman AK, Menter MA: Oral lesions in patients with psoriasis: a controlled study. Cutis 1992, 49:339-344[Medline]
-
Sklavounou A, Laskaris G: Oral psoriasis: report of a case and review of the literature. Dermatologica 1990, 180:157-159[Medline]
-
Van der Wal N, Van der Kwast WA, Van Dijk E, Van der Waal I: Geographic stomatitis and psoriasis. Int J Oral Maxillofac Surg 1988, 17:106-109[Medline]
-
Zhu JF, Kaminski MJ, Pulitzer DR, Hu J, Thomas HF: Psoriasis: pathophysiology and oral manifestations. Oral Dis 1996, 2:135-144[Medline]
-
Bork K, Hoede N, Korting GW: Mundschleimhaut- und Lippenkrankheiten, ed 2 1993, :pp 55-57 Schattauer, New York
-
Cawson RA, Binnie WH, Everson JW: Color Atlas of Oral Disease, ed 2. Hong Kong, Mosby-Wolfe, 1993, pp 1.141.15, and 12.2212.24
-
Hornstein OP: Erkrankungen des Mundes. Berlin, Kohlhammer, 1996, 187, pp 378382
-
Lotti TM, Parish LC, Rogers RS, III: Oral Diseases. 1999:pp 42-43 Springer, New York
-
Terui T, Ozawa M, Tagami H: Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000, 9:1-10[Medline]
-
Dimitrakopoulos I, Lazaridis N, Scordalaki A: Dermal psoriasis involving an oral split-skin graft. Case report. Aust Dent J 1998, 43:321-323[Medline]
-
Böckelmann R, Bonnekoh B, Gollnick H: Optimized visualization and PCR reamplification of differentially displayed cDNA bands detected by silver staining in polyacrylamide gels as established in the model of dithranol-treated keratinocytes. Skin Pharmacol Appl Skin Physiol 1999, 12:54-63[Medline]
-
Liang P, Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992, 257:967-971[Abstract/Free Full Text]
-
Neugebauer P, Bonnekoh B, Wevers A, Michel O, Mahrle G, Krieg T, Stennert E: Human keratinocyte culture from the peritonsillar mucosa. Eur Arch Otorhinolaryngol 1996, 253:245-251[Medline]
-
Bauer D, Müller H, Reich J, Riedel H, Ahrenkiel V, Warthoe P, Strauss M: Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucleic Acids Res 1993, 21:4272-4280[Abstract/Free Full Text]
-
Thompson NE, SteinbergTH, Aronson DB, Burgess RR: Inhibition of in vivo and in vitro transcription by monoclonal antibodies prepared against wheat germ RNA polymerase II that react with the heptapeptide repeat of eukaryotic RNA polymerase II. J Biol Chem 1989, 264:1151111520
-
Baskaran R, Dahmus ME, Wang JYJ: Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain. Proc Natl Acad Sci USA 1993, 90:11167-11171[Abstract/Free Full Text]
-
Schoen TJ, Chandrasekharappa SC, Guru SC, Mazuruk K, Chader GJ, Rodriguez IR: Human gene for the RNA polymerase II seventh subunit (hsRPB7): structure, expression and chromosomal localization. Biochim Biophys Acta 1997, 1353:39-49[Medline]
-
Khazak V, Sadhale PP, Woychik NA, Brent R, Golemis EA: Human RNA polymerase II subunit hsRPB7 functions in yeast and influences stress survival and cell morphology. Mol Biol Cell 1995, 6:759-775[Abstract]
-
Khazak V, Estojak J, Cho H, Majors J, Sonoda G, Testa JR, Golemis EA: Analysis of the interaction of the novel RNA polymerase II (pol II) subunit hsRPB4 with its partner hsRPB7 and with pol II. Mol Cell Biol 1998, 18:1935-1945[Abstract/Free Full Text]
-
Rivas MV, Jarvis ED, Morisaki S, Carbonaro H, Gottlieb AB, Krueger JG: Identification of aberrantly regulated genes in diseased skin using the cDNA differential display technique. J Invest Dermatol 1997, 108:188-194[Medline]
-
McKune K, Richards KL, Edwards AM, Young RA, Woychik NA: RPB7, one of two dissociable subunits of yeast RNA polymerase II, is essential for cell viability. Yeast 1993, 9:295-299[Medline]
-
Jensen GJ, Meredith G, Bushnell DA, Kornberg RD: Structure of wild-type yeast RNA polymerase II and location of Rpb4 and Rpb7. EMBO J 1998, 17:2353-2358[Medline]